Sterigentics International is seeking to turn its Nelson Labs business into a global extractables and leachables lab testing platform through its acquisition of Toxikon’s European division.
The purchase of Toxikon Europe, announced yesterday, represents a capabilities expansion when it comes to serving the pharmaceutical and medical device industries. Sterigenics’s Nelson Labs business will now offer Toxikon Europe’s extractables and leachables testing capabilities to its customers, while Nelson Labs’s microbiological services will be available to Toxikon Europe’s customers.
Financial terms of the deal were not disclosed.
Get the full story on our sister site Medical Design & Outsourcing.